2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T41f,- **Dupilumab/eosinophilia in children**: ~20% of children on dupilumab had early eosinophil increases (≥500 cells/µL at Week 12), but this did not affect long-term efficacy or safety. - **Gene-microbiome/wheeze**: 17q12-21 SNPs (esp. Gasdermin B rs7216389TT) interacted with MSH airway microbiota to increase early-life wheeze risk; CDSB microbiota interactions were protective. - **miR-149/skin**: Loss of miR-149 worsened psoriasis-like and atopic dermatitis-like inflammation in mice; restoring miR-149 in human biopsies suppressed inflammatory markers. - **Sulfasalazine SCARs**: HLA-B\*38:02 (OR 11.69 for SJS/TEN), HLA-B\*39:01 (OR 24.78 for DRESS), and HLA-B\*13:01 (OR 7.00 for DRESS); a 4-allele panel had 84.8% sensitivity in Chinese populations. - **SERPING1 SP variants**: 6 of 33 signal peptide variants caused poor C1-INH synthesis; protein aggregates observed in ER for L10R, G17R, S22L. - **Tezepelumab remission (TERESA)**: 34.6% of patients achieved clinical remission at 52 weeks; 47.4% biologic-naive vs 20.0% biologic-experienced.31:T695,To describe disease activity and treatments received during the postpartum period, breastfeeding rates and their possible impact on rheumatoid arthritis (RA) and spondyloarthritis (SpA) activity. This ancillary study from the French multicentre prospective cohort (GR2-NCT02450396) included pregnant women with RA and SpA with at least one postpartum visit from October 2014 to October 2022. Disease activity, flares, treatments and breastfeeding rates were described. Factors associated with the occurrence of a flare were evaluated by survival analysis. Disease activity was compared according to breastfeeding duration (never, <6 months and ≥6 months). Ninety-four RA and 124 SpA patients were studied. In RA patients, the proportion of patients presenting with at least one flare was significantly higher during the first 6 months postpartum compared with pregnancy (62.0% vs 43.5%; p=0.02). For SpA patients, there was no difference in disease activity at 6 months postpartum compared with pregnancy (40.7% vs 40.7%; p=0.999). Disease activity in postpartum was similar between the different breastfeeding status in both diseases. 13/91 (14.3%) RA patients and 29/123 (23.6%) SpA patients continued a biologic Disease-Modifying Antirheumatic Drug (bDMARD) during the whole pregnancy and the postpartum. 78/91 RA and 94/123 SpA patients delivered without any DMARDs, and among them, 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum. RA patients were more likely to flare during early postpartum, while SpA patients remained stable. bDMARD continuation during pregnancy was more frequent in SpA patients, and half of the patients restarted bDMARD during postpartum.32:T9b8, Objective To describe disease activity and treatments received during the postpartum period, breastfeeding rates and their possible impact on rheumatoid arthritis (RA) and spondyloarthritis (SpA) activity. Method This ancillary study from the French multicentre prospective cohort (GR2- NCT02450396 ) included pregnant women with RA and SpA with at least one postpartum visit from October 2014 to October 2022. Disease activity, flares, treatments and breastfeeding rates were described. Factors associated with the occurrence of a flare were evaluated by survival analysis. Disease activity was compared according to breastfeeding duration (never, <6 months and ≥6 months). Results Ninety-four RA and 124 SpA patients were studied. In RA patients, the proportion of patients presenting with at least one flare was significantly higher during the first 6 months postpartum compared with pregnancy (62.0% vs 43.5%; p=0.02). For SpA patients, there was no difference in disease activity at 6 months postpartum compared with pregnancy (40.7% vs 40.7%; p=0.999). Disease activity in postpartum was similar between the different breastfeeding status in both diseases. 13/91 (14.3%) RA patients and 29/123 (23.6%) SpA patients continued a biologic Disease-Modifying Antirheumatic Drug (bDMARD) during the whole pregnancy and the postpartum. 78/91 RA and 94/123 SpA patients delivered without any DMARDs, and among them, 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum. Conclusion RA patients were more likely to flare during early postpartum, while SpA patients remained stable. bDMARD continuation during pregnancy was more frequent in SpA patients, and half of the patients restarted bDMARD during postpartum. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"sulfasalazine: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on sulfasalazine (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/sulfasalazine\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"sulfasalazine\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/sulfasalazine\"}]}}"}}]],["$","$L2f",null,{"title":"sulfasalazine: Research & Clinical Takeaways","description":"Explore research on sulfasalazine (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1016/j.jaci.2026.07.012","pmid":null,"title":"The Editors’ Choice","journal_title":"Journal of Allergy and Clinical Immunology","journal_issn":"0091-6749","published_at":"2026-09-04T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaci.2026.07.012","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-09-07T06:30:44.540Z","updated_at":"2026-09-08T06:31:57.598Z","tags":[{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"age_group","value":"child","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"brand","value":"Dupixent","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Allergic Contact Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Asthma","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Drug Reaction With Eosinophilia And Systemic Symptoms","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Hereditary Angioedema","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Severe Cutaneous Adverse Reactions","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Stevens-Johnson Syndrome","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"condition","value":"Toxic Epidermal Necrolysis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"generic","value":"sulfasalazine","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"generic","value":"tezepelumab","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"modality","value":"Disease-Modifying Anti-Rheumatic Drug","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"sample_size","value":"n=107","value_numeric":107},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"study_design","value":"Editors' Choice / Multi-Study Summary","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"warning","value":"Level of evidence set to 2 reflecting the highest-quality design cited (prospective controlled trial/RCT components), but individual studies vary; the TERESA study is single-arm (level 3–4).","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"warning","value":"Sample size tag reflects only the TERESA tezepelumab trial (n=107), the only N explicitly stated in this summary; other studies' sample sizes are not provided in this text.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"warning","value":"The paper provided contains only metadata (title, DOI, journal, and publication date) with no abstract, methods, results, or conclusions. No content could be extracted for summaries or tags. The entry appears to be an 'Editors' Choice' editorial/collection notice rather than an original research article — the actual study content is not included.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"warning","value":"The sulfasalazine HLA genetic findings are derived exclusively from Asian populations (Taiwan, China, Japan, Malaysia, Thailand); applicability to non-Asian populations is not established.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.07.012","tag_type":"warning","value":"This is an editors' summary article covering 6 distinct studies — tags and summaries reflect highlights across all studies, not a single primary investigation.","value_numeric":null}],"summaries":{"what_studied":"This editors' choice issue summarizes 6 studies covering: dupilumab in children with asthma and transient eosinophilia (VOYAGE/EXCURSION trials, ages 6–11, ≤1 year + extension); gene-microbiome interactions and childhood wheeze; miR-149 as a skin inflammation regulator; HLA genetic markers for sulfasalazine-induced SCARs; SERPING1 signal peptide variants in HAE; and tezepelumab clinical remission in severe asthma (TERESA, n=107, 52 weeks).","key_result":"$30","limitations":"This is an editors' summary of multiple studies, not a single primary paper; individual study limitations (post hoc design for dupilumab analysis, single-arm phase 4 for TERESA, Asian-only cohorts for sulfasalazine genetics) apply to each respective article and are not fully detailed here.","practice_takeaway":"In children on dupilumab for asthma, an isolated early rise in eosinophils alone is unlikely to require stopping treatment. For sulfasalazine prescribing in Asian patients, preemptive HLA screening (especially B\\*38:02, B\\*39:01, B\\*13:01) can identify those at high risk for life-threatening skin reactions before starting therapy."}},{"doi":"10.1093/rheumatology/keag395","pmid":"42565551","title":"Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study","journal_title":"Rheumatology","journal_issn":"1462-0324","published_at":"2026-08-07T00:00:00.000Z","url":"https://doi.org/10.1093/rheumatology/keag395","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-19T06:28:55.988Z","updated_at":"2026-08-19T06:28:55.988Z","tags":[{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"condition","value":"Rheumatoid Arthritis","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"condition","value":"Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"generic","value":"mesalazine","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"generic","value":"sulfasalazine","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"modality","value":"Disease-Modifying Antirheumatic Drug","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"study_design","value":"Matched Cohort Study","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"warning","value":"Sample size not reported in the abstract or results excerpt; tags reflect available data only.","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"warning","value":"Study period ends June 2020; newer biologics (e.g., IL-17/IL-23 inhibitors) may not be well-represented in prescribing patterns.","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keag395","tag_type":"warning","value":"The IBD MCM finding (ORadj 1.31) reached borderline significance only on sensitivity analysis — authors caution against overinterpretation due to potential residual confounding.","value_numeric":null}],"summaries":{"what_studied":"This UK matched cohort study (CPRD, 2000–2020) examined prescribing patterns and pregnancy outcomes — spontaneous pregnancy loss and major congenital malformations (MCMs) — in women with RA, PsA, psoriasis, SpA, or IBD compared to matched women without these diagnoses. It also assessed outcomes in women exposed to azathioprine, mesalazine, and sulfasalazine.","key_result":"Spontaneous pregnancy loss risk was modestly elevated for psoriasis and IBD (IBD: HRadj 1.18, 95% CI 1.07–1.30), but not significantly increased for RA, PsA, or SpA (PsA: HRadj 1.01, 95% CI 0.79–1.28). MCM risk was not significantly raised for any IMID except IBD, where a borderline signal emerged on sensitivity analysis (ORadj 1.31, 95% CI 1.00–1.71). No increased spontaneous loss risk was seen with azathioprine, mesalazine, or sulfasalazine use.","limitations":"Residual confounding (e.g., disease activity, smoking, BMI) may explain the IBD MCM signal. The study relies on routinely coded primary care data, which may miss diagnoses or drug exposures. Individual IMID subgroup analyses (especially PsA, SpA) may be underpowered.","practice_takeaway":"Women with RA, PsA, or SpA can be counselled that their underlying condition does not appear to significantly raise spontaneous pregnancy loss risk; IBD carries a small but real increase. Azathioprine, mesalazine, and sulfasalazine use during pregnancy was not associated with increased spontaneous loss, supporting their continued use when clinically indicated."}},{"doi":"10.1007/s10067-026-08238-0","pmid":"42348128","title":"Uveitis in spondyloarthritis: clinical patterns and differences between axial and peripheral forms","journal_title":"Clinical Rheumatology","journal_issn":"0770-3198","published_at":"2026-06-25T00:00:00.000Z","url":"https://doi.org/10.1007/s10067-026-08238-0","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-03T13:38:42.087Z","updated_at":"2026-07-03T13:38:42.087Z","tags":[{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"condition","value":"Axial Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"condition","value":"Inflammatory Bowel Disease-Associated Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"condition","value":"Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"condition","value":"Uveitis","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"generic","value":"sulfasalazine","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"modality","value":"Biologic DMARD","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"modality","value":"Conventional Synthetic DMARD","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"sample_size","value":"n=163","value_numeric":163},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"study_design","value":"Retrospective Observational Study","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"warning","value":"Age group tagged as 'adult' — the paper does not explicitly state an age range or restrict enrollment to adults, but the SpA context and multidisciplinary uveitis clinic setting make a predominantly adult population highly likely.","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"warning","value":"Biologic drug names (e.g., adalimumab) are referenced in the literature review but not reported as distinct treatment arms in the results; they were not tagged as individual brands/generics to avoid misrepresentation.","value_numeric":null},{"paper_doi":"10.1007/s10067-026-08238-0","tag_type":"warning","value":"The impact flag 'confirms_prior' was applied because the study largely validates known clinical patterns; no single practice-changing finding was identified.","value_numeric":null}],"summaries":{"what_studied":"Retrospective observational study of 163 patients with non-infectious uveitis and spondyloarthritis (SpA) from a multidisciplinary uveitis clinic, comparing uveitis clinical patterns across SpA subtypes (radiographic axSpA, non-radiographic axSpA, IBD-SpA, psoriatic arthritis, peripheral SpA) and between axial vs. peripheral forms.","key_result":"Anterior uveitis (97%), acute relapsing course (79%), and alternating laterality (47.4%) dominated overall. Peripheral SpA forms showed exclusively non-anterior locations (intermediate, posterior, panuveitis), more chronic courses (p<0.001), more bilateralism (p<0.05), and greater systemic therapy use (p=0.05). Among all patients, 28.2% needed immunomodulatory therapy and 17.8% needed biologics.","limitations":"- Retrospective single-center design limits generalizability.\n- Peripheral SpA subgroups (pSpA 4%, PsA 12%, IBD-SpA 13%) were small, reducing statistical power for subgroup comparisons.\n- Biologic discontinuation difference in peripheral forms did not reach significance (p=0.059).","practice_takeaway":"Patients with peripheral SpA (including PsA and IBD-SpA) are at higher risk for non-anterior, chronic, and bilateral uveitis and need closer ophthalmologic monitoring and earlier consideration of systemic immunomodulatory therapy. Predictors of greater systemic therapy need include chronic course, bilateralism, frequent episodes, younger onset age, peripheral joint involvement, and vitritis."}},{"doi":"10.1136/rmdopen-2025-006593","pmid":"42049394","title":"Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort","journal_title":"RMD Open","journal_issn":"2056-5933","published_at":"2026-04-29T00:00:00.000Z","url":"https://doi.org/10.1136/rmdopen-2025-006593","source_score":17,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-30","doi":"10.1136/rmdopen-2025-006593","days":"14","issn":"2056-5933","rank":"6","field":"Clinical Medicine","score":"17","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1136/rmdopen-2025-006593","title":"Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort.","journal":"RMD open","methods":"This ancillary study from the French multicentre prospective cohort (GR2-NCT02450396) included pregnant women with RA and SpA with at least one postpartum visit from October 2014 to October 2022. Disease activity, flares, treatments and breastfeeding rates were described. Factors associated with the occurrence of a flare were evaluated by survival analysis. Disease activity was compared according to breastfeeding duration (never, <6 months and ≥6 months).","results":"Ninety-four RA and 124 SpA patients were studied. In RA patients, the proportion of patients presenting with at least one flare was significantly higher during the first 6 months postpartum compared with pregnancy (62.0% vs 43.5%; p=0.02). For SpA patients, there was no difference in disease activity at 6 months postpartum compared with pregnancy (40.7% vs 40.7%; p=0.999). Disease activity in postpartum was similar between the different breastfeeding status in both diseases. 13/91 (14.3%) RA patients and 29/123 (23.6%) SpA patients continued a biologic Disease-Modifying Antirheumatic Drug (bDMARD) during the whole pregnancy and the postpartum. 78/91 RA and 94/123 SpA patients delivered without any DMARDs, and among them, 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum.","abstract":"$31","keywords":["Arthritis, Rheumatoid","Axial Spondyloarthritis","Biological Therapy"],"pubmed_id":"42049394","conclusions":"RA patients were more likely to flare during early postpartum, while SpA patients remained stable. bDMARD continuation during pregnancy was more frequent in SpA patients, and half of the patients restarted bDMARD during postpartum.","publication_date":"2026-04-29T00:00:00"},"crossref":{"DOI":"10.1136/rmdopen-2025-006593","URL":"https://doi.org/10.1136/rmdopen-2025-006593","ISSN":["2056-5933"],"link":[{"URL":"https://syndication.highwire.org/content/doi/10.1136/rmdopen-2025-006593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"e006593","type":"journal-article","issue":"2","score":1,"title":["Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort"],"author":[{"given":"Marie","family":"Hornez","sequence":"first","affiliation":[{"name":"Service de Rhumatologie, Université de Lille, CHU Lille, Lille, France"}]},{"given":"Anna","family":"Molto","sequence":"additional","affiliation":[{"name":"Centre for Research in Epidemiology and Statistics, Université Paris Cité; Université Sorbonne Paris Nord; INSERM; INRAE, Paris, France"},{"name":"Service de Rhumatologie, Hôpital Bichat, APHP, Paris, France"}]},{"given":"Maxime","family":"Leroy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, CHU Lille, Lille, France"}]},{"given":"Béatrice","family":"Banneville","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France"}]},{"given":"Rakiba","family":"Belkhir","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicetre, France"}]},{"given":"Elodie","family":"Chauvet","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, CHU Montpellier, Montpellier, France"}]},{"given":"Marion","family":"Couderc","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand, France"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Caen, Caen, France"}]},{"given":"Valérie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne occidentale, Inserm, CHU Brest, LabEx IGO, Brest, France"},{"name":"Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU, Brest, France"}]},{"given":"Aline","family":"Frazier","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Paris Cité, AP-HP, Hôpital Lariboisière, Paris, France"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France"}]},{"given":"Elisabeth","family":"Gervais","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Poitiers, Poitiers, France"}]},{"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Jean Monnet Saint-Étienne, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Étienne, France"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, National Reference Center for Systemic Autoimmune Rare Diseases, Bordeaux University Hospital, Hôpital Pellegrin, Bordeaux, France"},{"name":"CNRS, Immunoconcept, UMR 5164, Bordeaux University, Bordeaux, France"}]},{"given":"Jérémie","family":"Sellam","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Hôpital Saint-Antoine; Assistance Publique–Hôpitaux de Paris (AP-HP); Sorbonne Université, Paris, France"}]},{"given":"Raphaele","family":"Seror","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicetre, France"}]},{"given":"Véronique","family":"Le Guern","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP Hôpital Cochin, Paris, France"}]},{"given":"Gaëlle","family":"Guettrot-Imbert","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP Hôpital Cochin, Paris, France"}]},{"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP Hôpital Cochin, Paris, France"}]},{"given":"René-Marc","family":"Flipo","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université de Lille, CHU Lille, FHU PRECISE, Lille, France"}]},{"given":"Jean-Guillaume","family":"Letarouilly","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université de Lille, CHU Lille, FHU PRECISE, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"}]}],"funder":[{"name":"the Association Prix Veronique Roualet"},{"id":[{"id":"10.13039/100011110","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100011110","name":"UCB","doi-asserted-by":"publisher"},{"name":"AFM-Telethon"},{"name":"Cochin Hospital"},{"name":"Association Francophone contre la Polychondrite chronique atrophiante"},{"id":[{"id":"10.13039/100020799","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100020799","name":"Association des Sclérodermiques de France","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100014034","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher"},{"name":"the French Society of Internal Medicine and Rheumatology"},{"name":"Association Gougerot Sjogren"},{"name":"The French Health Ministry"},{"name":"Lupus France"}],"issued":{"date-parts":[[2026,4]]},"member":"239","prefix":"10.1136","source":"Crossref","volume":"12","created":{"date-time":"2026-04-28T13:25:21Z","timestamp":1777382721000,"date-parts":[[2026,4,28]]},"indexed":{"date-time":"2026-04-29T12:21:56Z","timestamp":1777465316482,"date-parts":[[2026,4,29]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000,"date-parts":[[2026,4,28]]},"delay-in-days":27,"content-version":"unspecified"}],"subject":[],"abstract":"$32","accepted":{"date-parts":[[2026,3,31]]},"language":"en","relation":{},"resource":{"primary":{"URL":"https://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2025-006593"}},"subtitle":[],"deposited":{"date-time":"2026-04-28T13:25:26Z","timestamp":1777382726000,"date-parts":[[2026,4,28]]},"issn-type":[{"type":"electronic","value":"2056-5933"}],"published":{"date-parts":[[2026,4]]},"publisher":"BMJ","reference":[{"DOI":"10.1016/j.jbspin.2021.105289","key":"2026042806251264000_12.2.e006593.1","year":"2022","issue":null,"author":"Fakih","volume":"89","first-page":"105289","unstructured":null,"article-title":"Differences in distribution by department of prevalence and incidence of spondyloarthritis and inflammatory bowel diseases declared to the French National Health Insurance and their evolution between 2008 and 2018","journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbspin.2022.105460","key":"2026042806251264000_12.2.e006593.2","year":"2023","issue":null,"author":"Pina Vegas","volume":"90","first-page":"105460","unstructured":null,"article-title":"Prevalence, mortality, and treatment of patients with rheumatoid arthritis: A cohort study of the French National Health Data System, 2010-2019","journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hench PS . The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis. In: Classic Papers in Rheumatology. CRC Press, 2001.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1002/1529-0131(199906)42:6<1219::AID-ANR19>3.0.CO;2-G","key":"2026042806251264000_12.2.e006593.4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.24003","key":"2026042806251264000_12.2.e006593.5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.180226","key":"2026042806251264000_12.2.e006593.6","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-021-05588-9","key":"2026042806251264000_12.2.e006593.7","year":"2021","issue":null,"author":"Mokbel","volume":"40","first-page":"3465","unstructured":null,"article-title":"Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review","journal-title":"Clin Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/ard.2003.016881","key":"2026042806251264000_12.2.e006593.8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/key047","key":"2026042806251264000_12.2.e006593.9","year":"2018","issue":null,"author":"Ursin","volume":"57","first-page":"1064","unstructured":null,"article-title":"Disease activity during and after pregnancy in women with axial spondyloarthritis: a prospective multicentre study","journal-title":"Rheumatology (Sunnyvale)","doi-asserted-by":"crossref"},{"DOI":"10.3899/jrheum.180805","key":"2026042806251264000_12.2.e006593.10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.181067","key":"2026042806251264000_12.2.e006593.11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.1780370605","key":"2026042806251264000_12.2.e006593.12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/1529-0131(200005)43:5<1010::AID-ANR8>3.0.CO;2-O","key":"2026042806251264000_12.2.e006593.13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/ard.2007.084707","key":"2026042806251264000_12.2.e006593.14","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.20621","key":"2026042806251264000_12.2.e006593.15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-018-04415-y","key":"2026042806251264000_12.2.e006593.16","year":"2019","issue":null,"author":"Vieira Borba","volume":"38","first-page":"1263","unstructured":null,"article-title":"Prolactin, autoimmunity, and motherhood: when should women avoid breastfeeding?","journal-title":"Clin Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/rheumatology/kev404","key":"2026042806251264000_12.2.e006593.17","year":"2016","issue":null,"author":"Flint","volume":"55","first-page":"1693","unstructured":null,"article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1","journal-title":"Rheumatology (Sunnyvale)","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2015-208840","key":"2026042806251264000_12.2.e006593.18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.41191","key":"2026042806251264000_12.2.e006593.19","year":"2020","issue":null,"author":"Sammaritano","volume":"72","first-page":"529","unstructured":null,"article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","journal-title":"Arthritis Rheumatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"European Network of Pregnancy Registers in Rheumatology (EuNeP) . An overview of procedures and data collection. Arthritis Research & Therapy. Available: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2019-3 [Accessed 03 May 2023].","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/s13075-019-2019-3","key":"2026042806251264000_12.2.e006593.21","year":"2019","issue":null,"author":"Meissner","volume":"21","first-page":null,"unstructured":null,"article-title":"European Network of Pregnancy Registers in Rheumatology (EuNeP)-an overview of procedures and data collection","journal-title":"Arthritis Res Ther","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2020-218356","key":"2026042806251264000_12.2.e006593.22","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(23)00099-1","key":"2026042806251264000_12.2.e006593.23","year":"2023","issue":null,"author":"de Frémont","volume":"5","first-page":"e330","unstructured":null,"article-title":"Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study","journal-title":"Lancet Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2665-9913(22)00308-3","key":"2026042806251264000_12.2.e006593.24","year":"2022","issue":null,"author":"Murarasu","volume":"4","first-page":"e842","unstructured":null,"article-title":"Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study","journal-title":"Lancet Rheumatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.25","year":"2014","issue":null,"author":"van Riel","volume":"32","first-page":"65","unstructured":null,"article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)","journal-title":"Clin Exp Rheumatol","doi-asserted-by":null},{"DOI":"10.1016/j.jbspin.2022.105505","key":"2026042806251264000_12.2.e006593.26","year":"2023","issue":null,"author":"Valero","volume":"90","first-page":"105505","unstructured":null,"article-title":"Evaluating remission and low disease activity from the perspective of the patient with axial spondyloarthritis: The cross-sectional ConREspAx study","journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijmr.IJMR_701_15","key":"2026042806251264000_12.2.e006593.27","year":"2017","issue":null,"author":"Kumar","volume":"146","first-page":"S57","unstructured":null,"article-title":"Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation","journal-title":"Indian J Med Res","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.28","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Partial residuals for the proportional hazards regression model. ResearchGate; 2025. Available: https://www.researchgate.net/publication/30941900_Partial_Residuals_for_The_Proportional_Hazards_Regression_Model [Accessed 16 Sep 2025].","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1136/annrheumdis-2021-eular.420","key":"2026042806251264000_12.2.e006593.29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2021.722118","key":"2026042806251264000_12.2.e006593.30","year":"2021","issue":null,"author":"Wirestam","volume":"12","first-page":null,"unstructured":null,"article-title":"Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy","journal-title":"Front Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1136/ard-2022-222641","key":"2026042806251264000_12.2.e006593.31","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2018.08.008","key":"2026042806251264000_12.2.e006593.32","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/rmdopen-2022-002194","key":"2026042806251264000_12.2.e006593.33","year":"2022","issue":null,"author":"Kemper","volume":"8","first-page":null,"unstructured":null,"article-title":"Active counselling and well-controlled disease result in a higher percentage of women with rheumatoid arthritis that breast feed: results from the PreCARA study","journal-title":"RMD Open","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00404-022-06463-x","key":"2026042806251264000_12.2.e006593.34","year":"2022","issue":null,"author":"Allen","volume":"306","first-page":"1929","unstructured":null,"article-title":"Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare","journal-title":"Arch Gynecol Obstet","doi-asserted-by":"crossref"},{"DOI":"10.3389/fphar.2022.887462","key":"2026042806251264000_12.2.e006593.35","year":"2022","issue":null,"author":"Gerardi","volume":"13","first-page":null,"unstructured":null,"article-title":"Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis","journal-title":"Front Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13075-017-1269-1","key":"2026042806251264000_12.2.e006593.36","year":"2017","issue":null,"author":"van den Brandt","volume":"19","first-page":null,"unstructured":null,"article-title":"Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients","journal-title":"Arthritis Res Ther","doi-asserted-by":"crossref"},{"DOI":"10.3899/jrheum.171152","key":"2026042806251264000_12.2.e006593.37","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(15)01024-7","key":"2026042806251264000_12.2.e006593.38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.39","year":"2021","issue":null,"author":"Coulm","volume":"20","first-page":"10","unstructured":null,"article-title":"Allaiter en France aujourd’hui","journal-title":"Sages-Femmes","doi-asserted-by":null},{"DOI":"10.1016/j.jgyn.2015.09.026","key":"2026042806251264000_12.2.e006593.40","year":"2015","issue":null,"author":"Chantry","volume":"44","first-page":"1071","unstructured":null,"article-title":"Breastfeeding (part one): Frequency, benefits and drawbacks, optimal duration and factors influencing its initiation and prolongation. Clinical guidelines for practice","journal-title":"J Gynecol Obstet Biol Reprod (Paris)","doi-asserted-by":"crossref"},{"DOI":"10.1136/lupus-2021-000491","key":"2026042806251264000_12.2.e006593.41","year":"2021","issue":null,"author":"Ikram","volume":"8","first-page":null,"unstructured":null,"article-title":"Breastfeeding in women with rheumatic diseases","journal-title":"Lupus Sci Med","doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2017.00720","key":"2026042806251264000_12.2.e006593.42","year":"2017","issue":null,"author":"Tang","volume":"8","first-page":null,"unstructured":null,"article-title":"Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis","journal-title":"Front Immunol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]},"published-online":{"date-parts":[[2026,4,28]]}},"update-policy":"https://doi.org/10.1136/crossmarkpolicy","alternative-id":["10.1136/rmdopen-2025-006593"],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"original-title":[],"container-title":["RMD Open"],"published-print":{"date-parts":[[2026,4]]},"reference-count":42,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,28]]},"references-count":42,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct02450396"},{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct02450396"}],"short-container-title":["RMD Open"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1136/rmdopen-2025-006593","is_oa":true,"title":"Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort","updated":"2026-05-09T14:24:07+00:00","published_date":"2026-04-01","best_oa_location":{"url":"https://doi.org/10.1136/rmdopen-2025-006593","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1136/rmdopen-2025-006593"}}},"created_at":"2026-05-14T13:22:56.018Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"condition","value":"Rheumatoid Arthritis","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"condition","value":"Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"certolizumab pegol","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"sulfasalazine","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"modality","value":"Biologic Disease-Modifying Antirheumatic Drug","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"modality","value":"Biologic DMARD","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"modality","value":"TNF Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"sample_size","value":"n=218","value_numeric":218},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"study_design","value":"Prospective Cohort","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Certolizumab pegol is classified here under TNF alpha inhibitors and listed by generic name; no brand-level data were reported in the paper.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Definitions of flare and the specific disease activity measures are not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Disease activity scores were frequently missing, especially CRP, which may have reduced sensitivity to detect objective changes in activity.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Observational ancillary cohort analysis without randomized comparisons; causal inferences are limited.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Self-reported flare definitions may overestimate true flare rates compared to validated score-based definitions.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"The association between bDMARD resumption and postpartum flare is likely reverse causation (flare prompts treatment restart) rather than treatment causing flare—authors acknowledge this.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Treatment denominators (e.g., 91/123) differ from total enrolled (94/124), suggesting missing data or exclusions.","value_numeric":null}],"summaries":{"what_studied":"An ancillary analysis of a French multicentre prospective cohort (GR2) followed pregnant women with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who had at least one postpartum visit (2014–2022) to describe disease activity, flares, breastfeeding, and treatments. Postpartum disease activity was compared with pregnancy, flares were examined with survival analysis, and outcomes were explored by breastfeeding duration (never, <6 months, ≥6 months).","key_result":"In RA, the proportion with at least one flare in the first 6 months postpartum was higher than during pregnancy (62.0% vs 43.5%; p=0.02). In SpA, disease activity at 6 months postpartum was unchanged versus pregnancy (40.7% vs 40.7%; p=0.999); postpartum activity did not differ by breastfeeding status in either disease; 13/91 (14.3%) RA and 29/123 (23.6%) SpA continued a bDMARD through pregnancy and postpartum, and among those delivering without any DMARDs (RA 78/91; SpA 94/123), 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum.","limitations":"Only patients with at least one postpartum visit were included, and denominators varied across analyses (e.g., 91/123 vs totals 94/124), indicating missing data or exclusions. The abstract does not specify flare definitions or disease activity measures, and adjusted analyses are not reported.","practice_takeaway":"Plan closer monitoring of women with RA in the first 6 months after delivery, when flares were more frequent than during pregnancy; SpA activity appeared stable. Breastfeeding did not change postpartum activity, and many who stopped DMARDs in pregnancy restarted bDMARDs after delivery."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"sulfasalazine"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"sulfasalazine"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"sulfasalazine"}}}]]